Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Headache at Onset of Intracerebral Hemorrhage and Associations with Outcome
Cerebrovascular Disease and Interventional Neurology
P13 - Poster Session 13 (5:30 PM-6:30 PM)
4-021

To determine factors associated with headache at onset of intracerebral hemorrhage (ICH), as well as associations with long-term outcomes.

Headache is a frequent symptom of ICH, though its prognostic significance is unclear.

We performed a single-center cohort study using data from consecutive ICH patients over 12 months. ICH characteristics and outcomes were prospectively collected, while presenting symptoms were retrospectively abstracted using available documentation from pre-hospital emergency personnel and hospital-based providers. We determined factors associated with headache at ICH onset using logistic regression, then determined associations with unfavorable 3-month outcomes (defined as modified Rankin Scale 3-6) using logistic regression models adjusted for established ICH predictors and time from symptom onset to hospital arrival.

Of 311 patients in our cohort, 35% (n=108) had headache at onset. Patients with headache were younger than those without headache (mean age 66.8±15.5 vs. 72.6±15.2, p=0.002), had longer time-to-arrival (median 9.6 [IQR 2.1-28.8] vs. 3.4 [1.1-13.3] hours, p=0.002), and were more likely to have intact arousal (77% vs. 63%, p=0.04); female sex, hematoma volume, and location were not significantly different between groups. Adjusted models showed that headache at ICH onset was also associated with a history of migraine (OR 9.8, 95% CI 1.7-57.2), higher blood pressure on hospital arrival (OR per 10mmHg systolic BP 1.2, 95% CI 1.1-1.3), structural vascular lesions (OR 3.7, 95% CI 1.1-12.1), and subarachnoid extravasation (OR 2.9, 95% CI 1.4-5.9). Patients with headache at onset had significantly lower odds of unfavorable outcome (OR 0.27, 95% CI 0.13-0.54), an association that persisted in a sensitivity analysis excluding patients with impaired arousal and aphasia.

Patients with headache at ICH onset may be less likely to have unfavorable functional outcomes despite longer delays to hospital presentation, suggesting that ICH patients with headache may be phenotypically distinct from other ICH patients.

Authors/Disclosures
Michael Reznik, MD (Rhode Island Hospital)
PRESENTER
Dr. Reznik has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Morrison Mahoney. The institution of Dr. Reznik has received research support from NIDUS.
Scott Moody No disclosure on file
Tracy E Madsen No disclosure on file
Shadi Yaghi, MD (Hackensack Meridian Health) Dr. Yaghi has nothing to disclose.
Matthew Schrag, MD (Vanderbilt University) No disclosure on file
Ali Mahta, MD (Brown University) Dr. Mahta has received research support from Brown University Health.
Shyam S. Rao, MD (Rhode Island Hospital, Brown University) No disclosure on file
Christoph Stretz, MD, FÂé¶¹´«Ã½Ó³»­ (Brown University) The institution of Dr. Stretz has received research support from American Heart Association. The institution of Dr. Stretz has received research support from Duke University Medical Center/NIH. The institution of Dr. Stretz has received research support from University of Cincinnati/NINDS. The institution of Dr. Stretz has received research support from Biogen, Inc.. The institution of Dr. Stretz has received research support from Brown Physicians, Inc.. Dr. Stretz has a non-compensated relationship as a Editorial Board Member with Neurology: Clinical Practice that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities.
Linda C. Wendell, MD, FÂé¶¹´«Ã½Ó³»­ (Mount Auburn Hospital) Dr. Wendell has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various. An immediate family member of Dr. Wendell has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various. Dr. Wendell has stock in Apple. An immediate family member of Dr. Wendell has stock in Apple.
Bradford B. Thompson, MD (St. Elizabeth’s Medical Center) Dr. Thompson has nothing to disclose.
Karen L. Furie, MD (RIH/Alpert Medical School of Brown Univ) The institution of Dr. Furie has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen/BMS. Dr. Furie has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for BMJ/JNNP. The institution of Dr. Furie has received research support from NINDS.
Brian Mac Grory, MB BCh BAO (Duke University School of Medicine) An immediate family member of Dr. Mac Grory has received personal compensation for serving as an employee of Sanofi. Dr. Mac Grory has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Stroke. The institution of Dr. Mac Grory has received research support from National Institutes of Health. The institution of Dr. Mac Grory has received research support from American Heart Association.